Management of Genitourinary Syndrome of Menopause in Korean Breast Cancer Survivors by Fractional CO 2 Laser Treatment
Year: 2025
Type: article
Study design: Clinical Trial
Abstract: Purpose: Many breast cancer patients experience genitourinary syndrome of menopause (GSM) symptoms.Concerns about systemic absorption limit the use of local estrogen therapy, and clinicians are often hesitant to prescribe it to breast cancer survivors.Therefore, other treatment options are essential.The aim of this study was to examine the safety and effectiveness of fractional CO2 laser treatment in breast cancer survivors experiencing GSM.Materials and Methods: Each woman received three fractional CO2 treatments at 4-week intervals between sessions: baseline (V1), 4-week follow-up (V2), 8-week follow-up (V3), and a final follow-up at 12 weeks (V4).Breast cancer survivors who had one or more symptoms related to GSM qualified for inclusion in this study.Severity of symptoms was assessed with a visual analog scale (VAS) at baseline and every follow-up visit.We also measured GSM objectively using the vaginal health index score (VHIS) at every visit.At V4, patients evaluated their satisfaction with laser therapy using a 5-point Likert scale.Results: Twenty-four women were included in the study.Almost all symptoms showed improvement based on mean VAS score after treatment.Vaginal dryness and urgency improved after the second treatment.After completion of all treatments, all symptoms except frequency showed improvement.VHIS increased significantly after completion of laser treatment (8.5±3.1 at baseline vs. 16.2±2.9at V4; p<0.001).Conclusion: Fractional CO2 laser treatment appears to be an effective and safe method in breast cancer survivors with GSM.
Source: Yonsei Medical Journal
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $700
Award: G6030690408
OpenAlex ID: W4415566950